Skip to contentHome page Seeking Alpha - Power to InvestorsWeight LossApr 29, 2026, 2:40 AM ETLLY, NVOMarkit3.75K FollowersCommentsEarlier this month, Eli Lilly secured U.S. FDA approval for its once-daily obesity pill, orforglipron (brand name Foundayo), becoming only the second entrant in a nascent but potentially vast oral GLP-1 market.The approval follows Novo Nordisk A/S’s (NVO) launch of an oral version of Wegovy in January.Orforglipron is projected to generate about $1.6 billion in revenue in 2026, compared with $11.4 billion for Wegovy, which itself is seen easing from roughly $12.4 billion in 2025 as competition intensifies.Love Employee/iStock via Getty ImagesEarlier this month, Eli Lilly and Co. (LLY) secured U.S. Food and Drug Administration approval for its once-daily obesity pill, orforglipron (brand name Foundayo), becoming only the second entrant in a nascent but potentially vast oral GLP-1This article was written byMarkit3.75K FollowersIHS Markit (Nasdaq: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 key business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.